For this reason, the c-Myc expressing Myc-CaP prostate cancer cell line was applied because c-Myc expression reduced the activity of the mTOR inhibitor rapamycin in prostate cancer[65,66]. This evidence concerns the gene MTOR and prostate carcinoma.